

Remarks

Claims 1-82, 84, 85, 87, 88, 91-99, 103-130, and 142-144 have been canceled. Claims 83, 86, 89, 90, 100, 101, 102, 131-141 and 145-147 remain after amendment. Claims 148-154 have been added.

The Examiner has now further restricted the prosecution to a species represented by one of formulas IV-XVIII. Applicants select the species of formula XVII (claim 89), without traverse. Since the formulas V, X, XI, XVI (as amended) and XVIII (as amended), fall within the general formula of species XVII, they have been retained in the form of dependent claims.

The unifying concept in the remaining claims is that each is a pyrimidine nucleoside that has two non-hydrogen substituents in the 2'-position of the nucleoside, which represents the core of the invention. Applicants are not aware of any prior disclosure of the use of a pyrimidine nucleoside with a "2'-branched" carbon to treat these viruses.

Respectfully submitted,

Sherry M. Knowles, Esq.
Registration No. 33,052

Date: June 6, 2003

King & Spalding
191 Peachtree Street
Atlanta, Georgia 30303
Telephone: 404-572-3541
Facsimile: 404-572-5145